KURA

Kura Oncology, Inc. (KURA) ESG Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

No material environmental change this month; no new ESG-related news was provided.

R&D intensity remains high at 3.36x revenue, which can support innovation but also implies sustained resource use.

Social

No material social change this month; no new workforce, customer, or community news was provided.

Stock-based compensation remains elevated at 50.4% of revenue, which can affect employee alignment and dilution.

Governance

No material governance change this month; no new board, audit, or regulatory news was provided.

Liquidity remains strong with a current ratio of 4.73x and cash per share of 5.84, supporting financial resilience.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Kura Oncology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →